; ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and Strategic SWOT Analysis Review
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and Strategic SWOT Analysis Review

VIEWS: 12 PAGES: 44

ImmunoCellular Therapeutics, Ltd. (ImmunoCellular) is a clinical-stage biotechnology company. It undertakes the development of immune-based therapies to treat various types of cancers. The product pipeline of the company include active immunotherapies and patented monoclonal antibodies. The company’s product candidate portfolio includes peptide based vaccine to target cancer stem cells; cellular immunotherapies targeting cancer antigens, cancer stem cell antigens; and monoclonal antibodies to diagnose and treat several different cancers including glioblastoma multiforme (GBM), small-cell lung cancer, pancreatic cancer and ovarian cancer.

More Info
  • pg 1
									             ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and Strategic
                                 SWOT Analysis Review
        Reference Code: GDPH58556FSA                                                                                          Publication Date: APR 2012

          21900 Burbank Boulevard, 3rd Floor                 Phone              +1 818 9922907                  Revenue          NA
          Woodland Hills, CA                                 Fax                +1 818 9922908                  Net Profit       -5.72 (million USD)
          91367                                              Website            www.imuc.com                    Employees        3
                                                                                IMUC     [Over          The                      Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                Counter]                                         Healthcare

       Company Overview
       ImmunoCellular Therapeutics, Ltd. (ImmunoCellular) is a clinical-stage biotechnology company. It undertakes the development of
       immune-based therapies to treat various types of cancers. The product pipeline of the company include active immunotherapies
       and patented monoclonal antibodies. The company’s product candidate portfolio includes peptide based vaccine to target cancer
       stem cells; cellular immunotherapies targeting cancer antigens, cancer stem cell antigens; and monoclonal antibodies to
       diagnose and treat several different cancers including glioblastoma multiforme (GBM), small-cell lung cancer, pancreatic cancer
       and ovarian cancer.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      ImmunoCellular Therapeutics, Ltd., SWOT Analysis
         Manish Singh, Ph.D.                 Chief Executive Officer                  Strengths                              Weaknesses
         John S. Yu, M.D.                    Chairman
                                                                                      Focused Research and                   Product Development and
         Jacqueline Brandwynne               Director                                 Development Efforts                    Optimization
         Navdeep Jaikaria                    Director
                                                                                      Intellectual Property Portfolio
         Robert L. Martuza                   Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Portfolio of Clinical Programs         Uncertain R&D Outcomes
         ImmunoCellular Therapeutics, Ltd.
                                                                                      Key Business Initiatives               Competitive Landscape
        Share Price (USD) as on 13-Apr-                                  2.71
        2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.21        GlobalData
        Market Cap (million USD)                                         107
        Enterprise Value (million USD)                                   100
        Shares Outstanding (million)                                       39
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 27, 2012         ImmunoCellular Therapeutics To Present On
                                                                                                           Cancer Stem Cell Targeting At AACR Annual
                                                                                                           Meeting
                                                                                      Mar 21, 2012         ImmunoCellular Reports 2011 Results
                                                                                      Mar 16, 2012         ImmunoCellular Therapeutics Elects Richard
                                                                                                           Chin To Board
                                                                                      Feb 17, 2012         ImmunoCellular Therapeutics To Present At
                                                                                                           Targeting Stem Cells Symposium During 19th
                                                                                                           Annual Molecular Medicine Tri-Conference
       Source: Annual Report, Company Website, Primary and Secondary                 Source: Annual Report, Company Website, Primary and Secondary Research,
       Research, GlobalData                                                          GlobalData




ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and                                                                       Reference Code: GDPH58556FSA
Strategic SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       ImmunoCellular Therapeutics, Ltd. - Key Facts.................................................................................................................................. 5
       ImmunoCellular Therapeutics, Ltd. - Key Employees ......................................................................................................................... 6
       ImmunoCellular Therapeutics, Ltd. - Key Employee Biographies....................................................................................................... 7
       ImmunoCellular Therapeutics, Ltd. - Major Products and Services .................................................................................................... 8
       ImmunoCellular Therapeutics, Ltd. - Pharmaceutical Pipeline Products Data.................................................................................... 9
          ImmunoCellular Therapeutics, Ltd., Pipeline Products by Therapy Area ........................................................................................ 9
          ImmunoCellular Therapeutics, Ltd., Pipeline Products by Development Phase ........................................................................... 10
       ImmunoCellular Therapeutics, Ltd. - Medical Equipment Pipeline Products Data ............................................................................ 12
          ImmunoCellular Therapeutics, Ltd. Pipeline Products by Equipment Type................................................................................... 12
          ImmunoCellular Therapeutics, Ltd. Pipeline Products by Development Stage ............................................................................. 14
       ImmunoCellular Therapeutics, Ltd. - History .................................................................................................................................... 16
       ImmunoCellular Therapeutics, Ltd. - Company Statement ............................................................................................................... 19
       ImmunoCellular Therapeutics, Ltd. - Locations And Subsidiaries .................................................................................................... 20
          Head Office ................................................................................................................................................................................... 20
       Section 2 – Company Analysis ......................................................................................................................................................... 21
       ImmunoCellular Therapeutics, Ltd. - Business Description .............................................................................................................. 21
       ImmunoCellular Therapeutics, Ltd. - Corporate Strategy ................................................................................................................. 22
       ImmunoCellular Therapeutics, Ltd. - SWOT Analysis ...................................................................................................................... 23
          SWOT Analysis - Overview........................................................................................................................................................... 23
          ImmunoCellular Therapeutics, Ltd. - Strengths............................................................................................................................. 23
             Strength - Focused Research and Development Efforts ........................................................................................................... 23
             Strength - Intellectual Property Portfolio .................................................................................................................................... 23
          ImmunoCellular Therapeutics, Ltd. - Weaknesses ....................................................................................................................... 23
             Weakness - Product Development and Optimization ................................................................................................................ 23
          ImmunoCellular Therapeutics, Ltd. - Opportunities ....................................................................................................................... 24
             Opportunity - Portfolio of Clinical Programs .............................................................................................................................. 24
             Opportunity - Key Business Initiatives ....................................................................................................................................... 24
             Opportunity - Market Potential: Oncology.................................................................................................................................. 24
          ImmunoCellular Therapeutics, Ltd. - Threats ................................................................................................................................ 25
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 25
             Threat - Competitive Landscape ............................................................................................................................................... 25
             Threat - Stringent Government Regulations .............................................................................................................................. 25
       ImmunoCellular Therapeutics, Ltd. - Key Competitors ..................................................................................................................... 26
       Section 3 – Company Financial Ratios ............................................................................................................................................. 27
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 27
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 27
       Performance Chart ........................................................................................................................................................................... 28
       Financial Performance...................................................................................................................................................................... 28
       Financial Ratios - Interim Ratios....................................................................................................................................................... 29
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 30
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 31


ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and                                                                                                       Reference Code: GDPH58556FSA
Strategic SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                           
								
To top